These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38675189)

  • 1. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy.
    Kokkorakis N; Zouridakis M; Gaitanou M
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirk/dyrk1B Kinase in Ovarian Cancer.
    Friedman E
    Int J Mol Sci; 2013 Mar; 14(3):5560-75. PubMed ID: 23528858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells.
    Gao J; Zhao Y; Lv Y; Chen Y; Wei B; Tian J; Yang Z; Kong F; Pang J; Liu J; Shi H
    Cancer Cell Int; 2013 Jan; 13(1):2. PubMed ID: 23311607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirk kinase inhibition targets ovarian cancer ascites.
    Deng X; Hu J; Cunningham MJ; Friedman E
    Genes Cancer; 2014 May; 5(5-6):201-11. PubMed ID: 25061503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirk/Dyrk1B in cancer.
    Friedman E
    J Cell Biochem; 2007 Oct; 102(2):274-9. PubMed ID: 17583556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
    Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
    Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.
    Deng X; Hu J; Ewton DZ; Friedman E
    Carcinogenesis; 2014 Sep; 35(9):1968-76. PubMed ID: 24590896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
    Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
    J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.
    Deng X; Friedman E
    Genes Cancer; 2014 Sep; 5(9-10):337-47. PubMed ID: 25352950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2.
    Hu J; Nakhla H; Friedman E
    Int J Cancer; 2011 Jul; 129(2):307-18. PubMed ID: 20857490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer.
    Friedman E
    Cancers (Basel); 2010 Jul; 2(3):1492-512. PubMed ID: 24281169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of expression of the protein kinases DYRK1A and DYRK1B in cancer cells.
    Vorwerk VA; Wilms G; Babendreyer A; Becker W
    Sci Rep; 2024 Oct; 14(1):23926. PubMed ID: 39397076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.
    Deng X; Ewton DZ; Friedman E
    Cancer Res; 2009 Apr; 69(8):3317-24. PubMed ID: 19351855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M.
    Zou Y; Lim S; Lee K; Deng X; Friedman E
    J Biol Chem; 2003 Dec; 278(49):49573-81. PubMed ID: 14500717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling.
    Jin K; Lim S; Mercer SE; Friedman E
    J Biol Chem; 2005 Dec; 280(51):42097-105. PubMed ID: 16257974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirk/Dyrk1B controls ventral spinal cord development via Shh pathway.
    Kokkorakis N; Douka K; Nalmpanti A; Politis PK; Zagoraiou L; Matsas R; Gaitanou M
    Cell Mol Life Sci; 2024 Jan; 81(1):70. PubMed ID: 38294527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.